secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2026-09-08T21:25:14+00:00
Accession:  0001213900-26-098123
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma receives Nasdaq delisting notice for MVLS below $35M
--------------------------------------------------------------------------

- Nasdaq letter Sept 1, 2026: MVLS below $35M for 30 straight business days (Jul 21-Aug 31, 2026).
- Also fails alternative standards: stockholders' equity <$2.5M, net income <$500k.
- Compliance period until Mar 1, 2027; must hit $35M MVLS for 10 consecutive days.
- Common stock continues trading on Nasdaq Capital Market under ESLA; no immediate effect.
- Company to monitor MVLS and evaluate options; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/0001213900-26-098123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/ea030490301-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer